Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Consensus PT from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $4.50.

Several research analysts recently commented on the stock. Barclays cut their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday. Finally, Wall Street Zen lowered Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th.

Sangamo Therapeutics Stock Down 2.9%

NASDAQ:SGMO traded down $0.02 during trading hours on Tuesday, reaching $0.54. 3,149,689 shares of the company's stock were exchanged, compared to its average volume of 6,141,265. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The company has a 50-day moving average of $0.57 and a 200 day moving average of $0.99. The firm has a market capitalization of $126.12 million, a price-to-earnings ratio of -1.39 and a beta of 1.19.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The firm had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative return on equity of 345.98% and a negative net margin of 124.61%. Research analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several large investors have recently made changes to their positions in the company. Wealth Management Associates Inc. increased its position in Sangamo Therapeutics by 213.7% during the first quarter. Wealth Management Associates Inc. now owns 228,400 shares of the biopharmaceutical company's stock worth $150,000 after buying an additional 155,600 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Sangamo Therapeutics by 74.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock valued at $851,000 after acquiring an additional 555,323 shares in the last quarter. Caption Management LLC bought a new stake in Sangamo Therapeutics during the first quarter worth approximately $37,000. OMERS ADMINISTRATION Corp grew its holdings in Sangamo Therapeutics by 93.7% during the first quarter. OMERS ADMINISTRATION Corp now owns 207,800 shares of the biopharmaceutical company's stock valued at $136,000 after purchasing an additional 100,500 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Sangamo Therapeutics by 82.8% in the first quarter. Invesco Ltd. now owns 483,894 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 219,253 shares during the last quarter. Institutional investors own 56.93% of the company's stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.